Outlook Therapeutics
OTLK
15 hedge funds and large institutions have $16M invested in Outlook Therapeutics in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 15 → 15 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.01% less ownership
Funds ownership: 0.17% → 0.16% (-0.01%)
13% less capital invested
Capital invested by funds: $18.2M → $16M (-$2.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$526K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$429K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$46.7K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$40.8K |
| 5 |
Morgan Stanley
New York
|
+$19.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$788K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$525K |
| 3 |
Goldman Sachs
New York
|
-$390K |
| 4 |
JG
Jefferies Group
New York
|
-$296K |
| 5 |
PA
Perceptive Advisors
New York
|
-$208K |
OTLK Hedge Fund Activity: Q1 2017 in Review
15 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2017, worth a combined $16M — down 13% from $18.2M a quarter earlier.
Fund positioning in OTLK was balanced in Q1 2017: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $526K. The largest seller was Marshall Wace, exiting entirely with an estimated $788K sold.
- 15 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $16M of Outlook Therapeutics stock for Q1 2017, down 13% quarter-over-quarter.
- 4 funds opened new Outlook Therapeutics positions in Q1 2017 and 4 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics buyer in Q1 2017 was Cormorant Asset Management, an estimated $526K added.
- The largest Outlook Therapeutics seller in Q1 2017 was Marshall Wace, an estimated $788K sold.
Based on aggregated 13F filings for Q1 2017.